Timberlyne Therapeutics
PrivateLast Round
Series A
Jan 9, 2025
Total Funding Raised
$180M
Momentum Score
25 /100
Company Overview
Timberlyne Therapeutics is a biotechnology company pioneering novel medicines for serious neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Timberlyne Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Timberlyne Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 9, 2025 |
Key People
Founding team and executive leadership
Timberlyne Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series A |
| Boyu Capital | Series A |
| Mountainfield Venture Partners | Series A |
| Braidwell | Series A |
| 3H Health Investment | Series A |
| Venrock Healthcare Capital Partners | Series A |
| Abingworth | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 9, 2025
$180M round raised
Timberlyne Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Timberlyne Therapeutics's valuation, stock price, and market status.
